FY2024 · ended Oct 31, 2024 · Revenue $210,000, +0.0% YoY · Filed Jan 12, 2026
Anixa Biosciences, Inc. (ANIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jul 31, 2026 it held $13.9 million in cash and investments and $174,000 in total debt.
Revenue
$210,000
+0.0% vs prior year
Net income
$-10.93M
+13.0% vs prior year
Operating cash flow (TTM)
$-7.38M
-7.8% vs year-ago TTM
Free cash flow
$-6.19M
-25.9% vs prior year
EPS
$-0.34
+12.8% vs prior year
Dividend per share
None
Shares outstanding
33.38M
+3.7% vs prior year
Net cash
$13.69M
as of Jul 31, 2026
Operating margin
-6586.2%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANIX (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- DE
- Headquarters
- San Jose, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 715446
- Former names
- ITUS Corp (until Sep 27, 2018); COPYTELE INC (until Aug 27, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Oct 31, 2025 |
FY 2024 Oct 31, 2024 |
FY 2023 Oct 31, 2023 |
FY 2022 Oct 31, 2022 |
FY 2022 Oct 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $210,000 | $210,000 | — | $512,000 |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M |
| Diluted EPS | -$0.34 | -$0.39 | -$0.32 | — | — |
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M |
| Stockholders' equity | $15.2M | $20.0M | $24.3M | $29.0M | $35.4M |
| Cash and investments | $15.2M | $19.9M | $23.8M | $29.7M | $35.7M |
| Total debt | $204,000 | $232,000 | $175,000 | $221,000 | $259,479 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 9, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Jun 10, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Mar 11, 2026 | Mar 10, 2026 |
| 10-Q | Quarterly report | Mar 9, 2026 | Jan 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 9, 2026 | Feb 9, 2026 |
| 10-K | Annual report | Jan 12, 2026 | Oct 31, 2025 |
All 983 Anixa Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.